KarenAnneAutioMD

Instructor in Medicine. Assistant Attending Physician, Memorial Sloan-Kettering Cancer Center.

Overview of Dr. Autio

Dr. Karen Autio is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 10 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 40 publications and over 500 citings.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(213) 267-9130

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Virginia Medical CenterResidency, Internal Medicine, 2007 - 2010
Stony Brook University Health Sciences Center School of MedicineClass of 2007

Certifications & Licensure

CT State Medical License 2024 - 2025
NJ State Medical License 2021 - 2025
NY State Medical License 2010 - 2025
VA State Medical License 2007 - 2010

Clinical Trials

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
Active, not recruiting
Phase 1
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy Start of enrollment: 2013 Dec 18
Active, not recruiting
Phase 2
A Study of Olaparib and Durvalumab in Prostate Cancer Start of enrollment: 2019 Mar 07
Terminated
Phase 2
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Start of enrollment: 2019 Jul 11
Active, not recruiting
Phase 1, Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, Nivedita Chowdhury, Aditya Pratapa
Clinical Cancer Research. 2024-11-15
1 citations
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
Andrew T Lenis, Vignesh Ravichandran, Samantha Brown, Syed M Alam, Andrew Katims
Clinical Cancer Research. 2024-09-03
Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer.
Fourat Ridouani, H Alberto Vargas, Daniel J Holzwanger, Heiko Schöder, Emily Waters
European Urology Oncology. 2024-08-01

Lectures

Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), o...
2019 ASCO Annual Meeting - 6/1/2019
Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resista...
2019 ASCO Annual Meeting - 6/1/2019
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced so...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Immune Checkpoint Blockade in Prostate Cancer: It's All About the CombinationsAugust 10th, 2020
Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer ManagementMay 30th, 2024